Today: 10 June 2026
Browse Category

ASX:TLX 11 December 2025 - 10 April 2026

Telix (ASX:TLX) share price jumps 14% on 2026 revenue outlook — what moved the stock

Telix (ASX:TLX) share price jumps 14% on 2026 revenue outlook — what moved the stock

Telix Pharmaceuticals shares closed up 14.2% at A$10.43 in Sydney after reporting 2025 revenue rose 56% to US$803.8 million and forecasting 2026 revenue of US$950 million to US$970 million. The company filed for European approval of its TLX101-Px brain cancer imaging agent earlier in the week. Telix ended 2025 with US$141.9 million in cash and posted a US$5.3 million pre-tax loss.
20 February 2026
··
Telix stock price slides 8% as investors digest FY25 revenue update and China Illuccix filing

Telix stock price slides 8% as investors digest FY25 revenue update and China Illuccix filing

Telix Pharmaceuticals shares fell 7.7% to A$10.61 at Wednesday’s close after the company reported unaudited FY2025 revenue in line with guidance and noted early momentum for Gozellix. China’s drug regulator accepted the Illuccix application, triggering a formal review. Investors weighed ongoing U.S. regulatory developments and recent clinical trial results.
21 January 2026
··
Telix Pharmaceuticals (TLX) Stock Slides on Dec. 17, 2025: ProstACT Phase 3 Update, FDA Zircaix Overhang, Lawsuit Headlines, and Fresh Analyst Forecasts

Telix Pharmaceuticals (TLX) Stock Slides on Dec. 17, 2025: ProstACT Phase 3 Update, FDA Zircaix Overhang, Lawsuit Headlines, and Fresh Analyst Forecasts

Telix Pharmaceuticals shares fell 6.61% to A$11.73 on the ASX December 17, with volume at 6.36 million and a 52-week low of A$11.535. Nasdaq-listed shares dropped 6–7% in early U.S. trading. The company issued a statement confirming completion of Part 1 enrollment in its ProstACT Global Phase 3 study after market rumors. TLX591 has not received marketing authorization.
17 December 2025
···
Telix Pharmaceuticals (TLX) Stock: Varian Deal, ProstACT Milestone and Class Actions Redraw the 2025 Outlook

Telix Pharmaceuticals (TLX) Stock: Varian Deal, ProstACT Milestone and Class Actions Redraw the 2025 Outlook

Telix Pharmaceuticals shares fell 6% to US$9.33 in New York on December 11, near a 52-week low, despite trailing 12-month revenue of US$664 million and a new clinical partnership with Varian. The company faces SEC scrutiny, an FDA setback, and multiple class-action lawsuits, but continues to report late-stage oncology progress and expanding collaborations.
11 December 2025
···

Stock Market Today

  • Tech Stocks Rebound as Investors Buy the Dip After Nasdaq’s Worst Day in a Year
    June 9, 2026, 6:15 PM EDT. The Nasdaq Composite rebounded about 1% on Monday following a 4% drop on Friday, triggered by a strong U.S. jobs report that shifted Wall Street's interest rate outlook. The PHLX Semiconductor Index (SOX) surged over 5% despite rising Treasury yields and geopolitical tensions between Iran and Israel. Experts remain cautious: Bank of America projected a 6% year-end decline in the S&P 500, advising investors to "take profits" amid multiple sell signals historically linked to market peaks. Meanwhile, bullish investors expect broader market leadership and growth beyond high-flying memory and semiconductor stocks. New IPOs from SpaceX and AI companies Anthropic and OpenAI also attract attention as potential drivers of future market momentum.

Latest articles

Ford AI, energy gains pause after rally

Ford AI, energy gains pause after rally

10 June 2026
Ford shares dipped to $14.95 in late trading as investors weighed GM’s new sodium-ion battery partnership against Ford’s own $17 billion energy-storage rally, with May sales down 13.6% and EDF deliveries not expected until 2028, leaving the stock’s future tied to contracting momentum and regulatory advantages.
NuScale Tumbles as Nuclear-AI Trade Hits Bump

NuScale Tumbles as Nuclear-AI Trade Hits Bump

10 June 2026
NuScale Power plunged 7.2% to $10.00 on heavy volume as investors cut exposure to speculative nuclear stocks amid a Nasdaq selloff, with no new contracts announced and revenue down sharply year-over-year; the company’s future hinges on landing binding module deals and project financing, leaving shares sensitive to risk-off sentiment.
Visa, Mastercard get court win in $38 billion swipe-fee case

Visa, Mastercard get court win in $38 billion swipe-fee case

10 June 2026
Visa and Mastercard shares jumped 1.7% and 2% after a Brooklyn judge gave preliminary approval to their $38 billion swipe-fee settlement with U.S. merchants, a deal expected to save merchants $38 billion by 2031 and cap standard consumer-card rates at 1.25% for eight years, though major retailers and trade groups remain opposed.
Opendoor Faces Russell 3000 Deadline as Housing Market Remains Main Issue

Opendoor Faces Russell 3000 Deadline as Housing Market Remains Main Issue

9 June 2026
Opendoor shares rose 0.8% to $4.34 as investors positioned for its pending inclusion in the Russell 3000, set to take effect after June 26; index entry can boost demand from passive funds, but Opendoor’s Q1 revenue fell to $720 million with a wider $173 million net loss, and the company warned of risks from mortgage-rate volatility and housing market swings.
T1 Energy Stock Just Got Hit—KORE Deal Filing Puts Dilution Back in Focus

T1 Energy Stock Just Got Hit—KORE Deal Filing Puts Dilution Back in Focus

9 June 2026
T1 Energy shares plunged 7.4% to $8.46 after a new filing revealed details on stock-based payments for the KORE Power acquisition, raising dilution concerns as the deal’s share count will be set by a 10-day VWAP; a lower VWAP could mean more shares issued, pressuring existing holders amid sector-wide weakness and ongoing risks to closing and financing.
Go toTop